<?xml version='1.0' encoding='utf-8'?>
<document id="22101373"><sentence text="Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572)."><entity charOffset="82-93" id="DDI-PubMed.22101373.s1.e0" text="raltegravir" /><entity charOffset="98-110" id="DDI-PubMed.22101373.s1.e1" text="dolutegravir" /><pair ddi="false" e1="DDI-PubMed.22101373.s1.e0" e2="DDI-PubMed.22101373.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22101373.s1.e0" e2="DDI-PubMed.22101373.s1.e1" /></sentence><sentence text="In the modern era of highly active antiretroviral therapy (HAART), reluctance to perform transplantation (Tx) in HIV-infected individuals is no longer justified" /><sentence text=" Non-nucleoside reverse transcriptase inhibitors (NNRTIs) or protease inhibitors (PIs), the current first line regimens of HAART, are metabolized by the cytochrome P450 family (CYP3A4)" /><sentence text=" Most NNRTIs induce CYP3A4, whereas PIs inhibit it" /><sentence text=" Calcinuerin inhibitors (CNIs), which are mandatory for Tx, need the same enzyme complex for their clearance" /><sentence text=" Therefore, a significant drug-drug interaction (DDI) is encountered between current HAART and CNIs" /><sentence text=" This results in extreme difficulty in adjusting the optimal dose of CNIs, for which the therapeutic range is narrow" /><sentence text=" Of interest, integrase inhibitors (INIs) - novel, potent anti-HIV drugs - are mainly metabolized by uridine diphosphate glucuronosyltransferase (UGT) 1A1 and do not induce or inhibit CYP3A4"><entity charOffset="101-120" id="DDI-PubMed.22101373.s8.e0" text="uridine diphosphate" /></sentence><sentence text=" DDI is presumably absent when NNTRIs or PIs are replaced by INIs" /><sentence text=" Raltegravir (RAL), a first generation INI, has been introduced into kidney and liver Tx"><entity charOffset="1-12" id="DDI-PubMed.22101373.s10.e0" text="Raltegravir" /><entity charOffset="14-17" id="DDI-PubMed.22101373.s10.e1" text="RAL" /><pair ddi="false" e1="DDI-PubMed.22101373.s10.e0" e2="DDI-PubMed.22101373.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22101373.s10.e0" e2="DDI-PubMed.22101373.s10.e1" /></sentence><sentence text=" There is increasing evidence that rejection is well controlled without renal impairment due to CNI over-exposure while persistent, robust suppression of HIV is achieved" /><sentence text=" Global phase III clinical trials of dolutegravir (DTG), a second generation INI, are currently in progress"><entity charOffset="37-49" id="DDI-PubMed.22101373.s12.e0" text="dolutegravir" /><entity charOffset="51-54" id="DDI-PubMed.22101373.s12.e1" text="DTG" /><pair ddi="false" e1="DDI-PubMed.22101373.s12.e0" e2="DDI-PubMed.22101373.s12.e0" /><pair ddi="false" e1="DDI-PubMed.22101373.s12.e0" e2="DDI-PubMed.22101373.s12.e1" /></sentence><sentence text=" In vitro data has suggested that DTG may be less prone to resistance than RAL (referred to as having a higher genetic barrier)"><entity charOffset="75-77" id="DDI-PubMed.22101373.s13.e0" text="RAL" /><entity charOffset="34-36" id="DDI-PubMed.22101373.s13.e1" text="DTG" /><pair ddi="false" e1="DDI-PubMed.22101373.s13.e1" e2="DDI-PubMed.22101373.s13.e1" /><pair ddi="false" e1="DDI-PubMed.22101373.s13.e1" e2="DDI-PubMed.22101373.s13.e0" /></sentence><sentence text=" The time has come to extensively discuss the implications of INIs in Tx for HIV positive patients" /><sentence text="" /></document>